Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P19/00—Preparation of compounds containing saccharide radicals
  • C12P19/26—Preparation of nitrogen-containing carbohydrates

Definitions

• Chondroitin is a natural linear polysaccharide formed by alternating residues of N-acetyl-D-galactosamine ⁇ 1:4 and D-glucuronate ⁇ 1:3.
• chondroitin is present in various sulphated forms originated by sulfation of hydroxyl residues 4 and 6 of N-acetyl-D-galactosamine and, in some cases, of residues 2 and 3 of glucuronic acid (Sugahara K et al., J. Biol. Chem., 1996, 271, 26745-54).
• chondroitin and the extent and sites of sulfation depend on the type and age of tissues (Kuettner K E et al., Eds., in Articular cartilage and osteoarthritis, NY, Raven Press, 1992; Volpi N Ed., in Chondroitin sulfate: structure, role and pharmacological activity, S. Diego, Calif. Academic Press-Elsevier Inc, 2006). Chondroitin sulfate belongs to the wider family of glycosaminoglycans, termed GAGs (Beaty N B, and Mello R J, J. Chromatography and Biomedical Applications, 1987, 418, 187-222).
• pathogenic bacteria produce a capsular structure that serves as a virulence factor.
• the capsule is formed by GAG or related structures in order to trick the immune system during infection.
• pathogens are Pasteurella multocida (DeAngelis P L, et al., Carbohydrate Res. 2002, 337(17), 1547-52; Harper M, et al., FEMS Microbiol. Lett., 2006, 265(1), 1-10; Leonov A V, et al., Zh. Mikrobiol. Epidemiol. Immunobiol. 2006, November-December (7), 94-7), encapsulated strains K4 and K5 E. coli (Roberts I S, Ann. Rev. Microbiol.
• Chondroitin sulfate is used as anti-rheumatic and chondroprotective drug, with applications in the treatment of tibiofibular osteoarthritis of the knee and osteoarthritis of the articular cartilage (Kuettner K E et al., Eds., in Articular cartilage and osteoarthritis, NY, Raven Press, 1992; Simànek V et al., 2005, 149, 51-56; Goerres G W et al., J.
• chondroitin sulfate is obtained by extraction techniques from various animal sources, such as pig cartilage, shark fin and cartilage from teleosts.
• the chondroitin sulfate obtained by extraction may be excluded from the pharmaceutical market due to increasingly stringent regulations on the safety of animal-derived drugs, that are continuously enacted.
• EP 1950308 and a series of previous patent documents describe methods for in vitro synthesis of chondroitin and its derivatives using chondroitin synthase from E. coli K4 and its mutants, which have only one of the two transferase activities.
• U.S. 20070059805 claims the structure of human chondroitin synthase, an expression vector comprising the sequence of the enzyme, the expression of said vector in eukaryotic cells and a method to synthesize the polysaccharide chain of chondroitin.
• chondroitin can be produced by fermentation obtaining yields >8 gL ⁇ 1 by use of an integrated strategy based on optimization of a three-phase fermentation process (batch-fed batch-in microfiltration regimen) and genetically modified bacteria.
• Said bacteria are preferably genetically modified strains of E. coli K4, whereby the aim of the engineering process is to improve processivity of the whole enzyme complex responsible for the synthesis of the K4 polysaccharide, by inserting multiple copies of the autologous RfaH gene, which acts as positive regulator of transcription of the gene cluster responsible for the synthesis of capsular material.
• the fermentation process developed, integrated with a strategy of site-selective chemical sulphation of chondroitin makes the claimed biotechnological process competitive compared to the conventional processes of extraction of chondroitin sulfate from raw materials of animal origin, which may be removed from the pharmaceutical market due to recent changes of regulations about product safety.
• the present invention describes a fermentation process which, by use of genetically modified bacterial microorganisms such as E. coli , preferably K4, and by use of special growth conditions allows production of capsular polysaccharides, chondroitin precursors (chondroitin fructosylated on glucuronic acid in position 3, in the case of polysaccharide K4) and to obtain yields higher than 8 g ⁇ L ⁇ 1 , that is about 20-fold more than hitherto described.
• genetically modified bacterial microorganisms such as E. coli , preferably K4
• special growth conditions allows production of capsular polysaccharides, chondroitin precursors (chondroitin fructosylated on glucuronic acid in position 3, in the case of polysaccharide K4) and to obtain yields higher than 8 g ⁇ L ⁇ 1 , that is about 20-fold more than hitherto described.
• the process claimed is inventive and innovative compared to the prior art, because it is the only one that allows implementation of processes on an industrial scale for production of chondroitin, a polysaccharide of great potential for the pharmaceutical market, for which no production, extraction or biotechnological processes have been achieved up to now. Furthermore, the process claimed, integrated with a strategy of site-selective sulfation of chondroitin, now makes possible to meet the growing demand of chondroitin sulfate that comes from the market, bypassing the problems of current production strategies based on extraction and associated with the use of animal sources.
• E. coli K4 Wild type E. coli K4 (EcK4wt)—There are many known strains of E. coli , all encapsulated, categorized in four different serological groups based on the capsular antigenic determinants (about 80 antigenic determinants are known to date) and on physical, biochemical and genetic criteria. Capsules of group 1 and 4 belong to strains of E. coli responsible for intestinal infections including enteropathogenic (EPEC), enterotoxigenic (ETEC) and enterohemorrhagic (EHEC) strains. Group 1 capsules are formed by polysaccharides which are acidic due to the presence of uronic acids with quite similar structures.
• Group 4 capsular structures are instead very different and are characterized by the presence of Nacetylated amino sugars in their repeating units.
• Capsules in groups 2 and 3 belong to strains of E. coli responsible for extraintestinal infections (ExPEC).
• EcK4wt the microorganism subjected to genetic modification for over-production of the K4 polysaccharide, belongs to serological group 2 and is available with different codes in the major banks of microorganisms such as American Type Culture Collection, USA (ATCC 23502), International Escherichia Centre, Denmark (strain Bi 8337/41), National Collection of Type Cultures, UK (strain NCTC 9005) and Freiburg collection (strain U1-41 2616).
• EcK4wt carries an endogenous plasmid, henceforth identified with the acronym PK4, whose presence in E. coli K4 is not described in the literature.
• pK4 consists of about 93,000 bases, is constitutive and is characterized in that it comprises sequences that can be used to insert the heterologous gene sequences ID NO:1 e/o ID NO:6. On average it is present in 1-5 copies/cell and its genetic modifications are stable.
• RfaH the transcriptional regulator of the gene cluster responsible for the synthesis of capsular material—The transcription of long polycistronic operons in bacteria is often based on accessory proteins, whose molecular mechanisms remain unknown. For example, transcription of a single mRNA molecule from regions 2 and 3 of the gene cluster responsible for the synthesis of molecular components of the capsule is controlled by a protein encoded by the antiterminator gene rfaH, which therefore functions as a positive regulator of transcription, preventing the premature arrest of transcripts.
• the protein encoded by the RfaH gene activates transcription of several genes responsible for virulence and fertility of enteric bacteria (Stevens M P et al. Mol.
• the protein encoded by the RfaH gene is required for biosynthesis of the lipopolysaccharide core of E. coli and S. typhimurium (Pradel E and Schnaitman C A, J. Bacteriol., 1991, 173, 6428-31; Brazas R, et al., J. Bacteriol. 1991, 173, 6168-73), for the synthesis and secretion of ⁇ -hemolysin (Bailey M J A et al., Mol. Microbiol. 1992, 6, 1003-10) and for the production of sex factor-F (Beutin L and Achtman M J, Bacteriol.
• the rfaH gene is under control of a regulated promoter, which determines maximum expression during the stationary growth phase (Stevens M P, et al. Mol. Microbiol., 1997, 24, 1001-12; Stevens M. P., et al., FEMS Microbiol. Lett., 1994, 124, 93-98).
• the integrated rfaH gene can be placed under the control of a promoter which is preferably efficient at all stages of growth, such as pGap, a constitutive promoter of the GapA gene encoding the glyceraldehyde-3-P-dehydrogenase (GAPDH) which is a key enzyme necessary for E. coli metabolism.
• a promoter which is preferably efficient at all stages of growth, such as pGap, a constitutive promoter of the GapA gene encoding the glyceraldehyde-3-P-dehydrogenase (GAPDH) which is a key enzyme necessary for E. coli metabolism.
• the pGap promoter is organized in a multi-promoter region composed of P1, P2, P3 and P4 promoters.
• P1, P2, P3 and P4 promoters are the strongest, however the four promoters act synergistically to ensure gene transcription in different conditions, making it more versatile and efficient.
• Other constitutive promoters which are active in E. coli can still be used.
• a bacterial strain having a chondroitin precursor as capsular polysaccharide, preferably an engineered Escherichia coli strain, in which said polysaccharide is preferably K4, characterized in that it comprises at least one copy of a sequence coding the rfaH protein or its functionally equivalent fragments.
• This can be engineered by insertion of multiple gene copies as chromosomal DNA elements or as plasmid elements or transposable elements, alternatively or in combination.
• the sequence coding for the rfaH protein is placed under the control of a constitutive promoter or comprises at least one sequence selected from the group consisting of: SEQ ID NO:1 SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20.
• the first batch phase lasts until a decrease in microbial ( ⁇ ) growth rate occurs as result of nutrient depletion, leading to a simultaneous increase of pO 2 .
• the second fed-batch phase is critically characterized by a feeding profile that makes use of a concentrated solution of nutrients supporting microbial growth to a rate that is less than maximal.
• the claimed fermentation strategy involves the possibility that addition of nutrients is automatically optimized by driving the feed with variations of fermentation parameters typically correlated with conditions of nutrient availability, such as partial O 2 pressure or pH of the culture medium.
• This strategy is implemented by creating control loops with a dedicated software ensuring, based on optimized parameters of PID controllers, real-time adjustments in order to meet the nutritional requirements of microbial growth, thereby prolonging the growth phase and avoiding metabolism overflow phenomena which could lead to accumulation in the medium of organic acids inhibitory to growth (in the case of EcK4 a concentration of acetic acid>5 g ⁇ L ⁇ 1 inhibits growth).
• microfiltration regimen is activated when the accumulation of toxic catabolites slows down or stops growth, even in presence of available nutrients.
• This process involves microfiltration of the culture medium using microfiltration modules placed inside or outside the bioreactor.
• the fermented volume is kept constant by a level controller, which automatically restores the volume of the micro-filtrate removed by addition of saline with composition compatible with that used for medium preparation.
• the K4 polysaccharide is present partly in microfiltrate and partly in the fermentor.
• K4 polysaccharide For production of K4 polysaccharide, culture media with different composition can be used for growth of EcK4r and EcK4wt; for example, glucose, dextrin, starch, glycerol, corn steep liquor, molasses can be used as carbon sources and peptone, yeast extract, casein hydrolysate, tryptone and soy, cotton and pea flours can be used and as non-animal sources of organic nitrogen and complex nutrients.
• the ratio between carbon source and organic nitrogen source in the culture medium is critical for efficient production (K4 polysaccharide/biomass). In particular, decreasing the amount of organic nitrogen in the culture medium results in lower growth capacity of the microorganism, associated with a greater ability to produce the K4 polysaccharide. Since this second effect outweighs the first, a higher productivity (polysaccharide K4/L fermentation) is observed in semidefined media poor in complex sources.
• Oxygenation of the culture medium has no critical effects on growth of the microorganism and production of K4 polysaccharide, as long as conditions of strict anoxia are avoided, ensuring at least a pO 2 >5% saturation in pure oxygen.
• pH—growth occurs between pH 3 and 10, while the pH range 6-8 is optimal for growth of the microorganism and for production of K4 polysaccharide. Therefore, the pH of the culture medium is automatically maintained within this pH interval with a pH-stat system.
• the microorganism releases the K4 polysaccharide in the culture medium, partially in the exponential growth phase and completely in the stationary phase.
• a feed phase of concentrated nutrient supply starts and restores pO 2 to the setting value, with low drift ( ⁇ 20% of p O 2 set).
• the feeding pump stops automatically and shuts off feeding, until the carbon source in the fermentation broth is depleted, resulting in a sudden rise of the pO 2 value and triggering a new cycle as described above.
• the feed phase then proceeds automatically and sequentially according to the nutritional requirements of the culture under metabolic control.
• a similar strategy of feed driving can be activated by working on pH variations; in this case it is necessary to exclude the automatic pH-stat system for pH adjustment, feeding will be inserted via a on-switch of the adduction pump when pH increases above a predefined threshold, based on physiology of the microorganism (e.g. pH 7.8).
• microfiltration process is carried out with an external unit, preferably made of hollow fibers, operating under a tangential microfiltration regimen, which reduces fouling of membrane filters and maintains a high transmembrane flow.
• the volume of the micro-filtrate is automatically restored with saline solution with composition identical to the culture medium, using a level control.
• nutrients are added in the form of concentrated solution, according to a feeding profile that is limiting for growth rate. This allows to avoid undesired metabolic overflow phenomena and the loss of nutrients in the output current (eluate) of the micro-filtered culture medium.
• the permeate obtained in the third phase of the fermentation process contains low levels of macromolecular contaminants (e.g. proteins, LPS, etc.) owing to the resistance of the membrane (Rm) and the cake resistance (Rc) that is formed on the membrane. Therefore, it is possible to treat such permeate directly on the ultrafiltration (UF) membrane, avoiding protease pre-treatment, which is instead required for the depleted culture broth after removal of the cellular component. Alternatively, the microfiltration permeate is added to the depleted culture broth devoid of the cellular component.
• macromolecular contaminants e.g. proteins, LPS, etc.
• biomass removal can be achieved either by microfiltration or centrifugation or by use of earth filtration through Funda Plate filters.
• Removal of biomass by microfiltration continues at the end of the fermentation process, interrupting the addition of saline.
• the amount of biomass in the microfiltrate reaches the maximum value compatible with the process (300-400 g of wet biomass L ⁇ 1 , corresponding to a concentration 3-5 fold the volume of fermentation broth) one volume of deionized water is added and microfiltration is continued; this washing step is repeated at least 3 times. All permeates produced during fermentation and those associated with the removal of biomass (acellular medium) are pooled and subjected to subsequent steps of the downstream process.
• the culture broth may be collected in a sanitized container and processed on a specific automated system for cross-flow microfiltration, using cassette or preferably hollow fibers with a cutoff between 0.22 and 0.6 m.
• the operating conditions involve a T comprised between 15° C. and 40° C., a transmembrane pressure between 0.8 and 1.2 atm and a capacity for recirculation of tangential flow of 40-100 L ⁇ (min ⁇ m 2 ) ⁇ 1 . Imposing a higher ⁇ p ( ⁇ 0.5 atm) results in an increase of transmembrane flow and shorter treatment times, but causes formation of a thicker cake which prevents full recovery of the K4 polysaccharide in the eluate.
• an amount of earth filter preferably Celite
• the suspension is then fed into a FUNDA type plate filter, and filtered under pressure (3-6 bar).
• the clarified broth (OD600 ⁇ 0.1) can be treated for protein degradation possibly after microfiltration through special asymmetric microfiltration capsules (e.g. GE from 0.6 to 0.2 m).
• proteolytic enzymes are added, preferably fungal proteases ( Aspergillus oryzae 2-6 UL ⁇ 1 ) and allowed to act for a time length dependent on the temperature used (1-3 h at 25-37° C., 8-20 h at 4° C.).
• Ultrafiltration-diafiltration The fermented material, devoid of the cellular component and deproteinized, is ultrafiltrated by use of manual or automatic systems for tangential ultrafiltration (UF) equipped with membranes assembled as cassette or hollow fiber modules, made of material compatible with the process, preferably polyethersulfone or polypropylene, with a cut-off of 50-300 KDa, preferably 100 KDa and with an area comprised between 0.02 and 0.05 m 2 per liter to be treated.
• UF process parameters are: capacity for tangential flow recirculation 4-10 L ⁇ min ⁇ 1 ; trans-membrane pressure 0.5-1.4 atm; temperature 20-40° C.; pH 4-8.
• the culture broth devoid of cells and deproteinized, possibly supplemented with the permeate from the fermentation phase, if it was not treated separately, is concentrated up to 10-20 fold the initial volume to remove low molecular weight contaminants (salts, peptides, residual nutrients). Subsequently, the concentrate is diafiltrated with deionized or ultrapure water (HPW 2-5 volumes) to complete the removal of low molecular weight components.
• Acid treatment The concentrate is subjected to acid hydrolysis with the dual purpose of defructosylating the K4 polysaccharide, forming chondroitin and fructose, and detoxifying the LPS lipopolysaccharide, separating the polysaccharide component (O-chain) from the lipid component (A lipid) that precipitates.
• hydrolytic conditions are: acetic acid from 0.5 to 3.0% (v/v), pH 2-4, temperature 60-100° C., hydrolysis time 1-3 h. After removal of the lipid component of LPS by centrifugation, filtration or microfiltration, the solution brought to neutral pH and mixed with an equal volume of a 0.1-0.2 M NaCl solution, is again concentrated-diafiltrated.
• acid hydrolysis (4-5% acetic acid pH ⁇ 3, 1-3 h 100° C.) can be performed after deproteinization on the unconcentrated clarified broth.
• This experimental process also results in lipopolysaccharide hydrolysis with subsequent release of lipid A and its precipitation as well as in defructosylation of K4 polysaccharide, thereby generating chondroitin.
• the culture broth After hydrolysis the culture broth is cooled and centrifuged, the supernatant is adjusted to pH 7, supplemented with NaCl and then concentrated and diafiltrated to remove O-chain and residual components of the medium.
• the membranes used are made of material compatible with the process, preferably polypropylene or polyethersulfone, and have a cut-off of 10-100 kDa, preferably 50 KDa, and a filter area of 0010-0005 m 2 per liter to be treated.
• Membrane size is limited since defructosylation involves approximately 30% difference between the molecular weight of the K4 polysaccharide and that of chondroitin, therefore the selected molecular cut off range choice allows good recovery, while maintaining the effect of purification from low molecular weight contaminants (sodium acetate, other salts, peptide residues, O-chains).
• Examples of operating ranges of UF process parameters are: Capacity for tangential flow recirculation 4-10 L ⁇ min ⁇ 1 ; trans-membrane pressure 0.8-1.4 atm; temperature 20-40° C., pH 5-8. The supernatant is concentrated up to 3-5 fold the initial volume to remove most low molecular weight contaminants (fructose, O-chains, salts) is then diafiltrated with deionized water (5.2 volumes) to complete the removal of the low molecular weight component, and push the separation of O-chains (10-15 KDa) from defructosylated chondroitin (30-50 KDa).
• Chondroitin present in the retentate can be retrieved either: a) by precipitation with organic solvents (2-5 volumes of 95% ethanol v/v or acetone in the presence of 0.1-0.3M sodium chloride) and subsequent heat desiccation under vacuum; b) by lyophilization; c) by spray-drier.
• the claimed downstream process enables recovery >80% of the theoretical value and leads to production of >95% pure chondroitin with an endotoxin content reduced by a factor >10 4 , a protein content ⁇ 0.05% and MW 30-50 KD.
• EcK4r1 E. coli K4 recombinant 1
• the strategy used for construction of recombinant EcK4r1 involves the integration, into the multiple copies (1-5) of the endogenous PK4 plasmid of EcK4wt (wild type K4 E. coli ), of an expression cassette containing the rfaH gene under control of pGapP1 (partial constitutive P1 promoter of the gene encoding glyceraldehyde-3-P dehydrogenase, GAPDH) in order to obtain constant transcription of the rfaH gene throughout the growth phase.
• pGapP1 partial constitutive P1 promoter of the gene encoding glyceraldehyde-3-P dehydrogenase, GAPDH
• the cassette provided in the kit is amplified using the primer pair pK4_up and FRT_dw (Table 1).
• the pK4_up oligo contains a 50 bp region similar to the 5′ portion of the PK4 plasmid, where the recombination event is meant to be targeted.
• the PCR profile used was: 94° C. for 2′; 25 cycles: 94° C. for 1′, 56° C. for 1′, 72° C. for 2′; 72° C. for 30′′.
• Pgap (P1) promoter (fragment II)—EcK4wt chromosomal DNA is used as template for amplification of the glyceraldehyde-3-phosphate dehydrogenase promoter.
• pGap_up and pGap_dw primers are used for the PCR reaction according to the following profile: 94° C. for 2′; 25 cycles: 94° C. for 30′′, 52° C. for 30′′, 72° C. for 30′′.
• Amplification of the rfaH gene is carried out using EcK4wt chromosomal DNA as template and primers rfaH_up and pK4_dw (Table 1). The latter contains 50 bp which are homologous to the 3′ portion of plasmid PK4 where the recombination event is meant to be directed.
• the PCR profile used was: 94° C. for 2′; 25 cycles: 94° C. for 1′, 56° C. for 1′, 72° C. for 30′′; 72° C. for 7′.
• the amount of LM DNA used to calculate the amount of Lm to be added to the reaction is 100 ng.
• 5 U of T4 DNA ligase are added to the reaction mix along with the specific enzyme buffer (1 ⁇ final concentration). The reaction is incubated at 16° C. for 12 h.
• First ligase reaction The first ligase reaction is done with fragments I and II. The resulting product is electrophoresed in 1% agarose gel, excised and purified as described above.
• Second ligase reaction The second ligase reaction is done with the sequence obtained from the first ligase reaction (fragm. I+II) and fragment III (rfaH), reproducing the above conditions.
• the complete cassette fragment I+II+III, about 2,500 bp
• XL-Vector Cloning in XL-Vector—The whole integration cassette is inserted in the XL cloning vector (Invitrogen), which is characterized by T-protruding ends. Taq polymerase catalyzes the addition of an extra A at the 3′ end of transcripts (TA cloning). Following the protocol provided by the manufacturer, 1 ⁇ L of vector is mixed with 4 ⁇ L of PCR product and incubated at room temperature for 5 min. The sample is briefly mixed and placed in ice.
• E. coli TOP10 Transformation of E. coli TOP10 by electroporation—Electro-competent E. coli Top10 cells (Invitrogen) are transformed by electroporation to allow entry of the XL-PgaprfaH vector. A 40 ⁇ L aliquot of the cell suspension is transferred to 0.2 cm cuvettes to which the vector-insert mixture is added. The sample is incubated in ice for about 1 min and then placed in the elecroporator cell (Bio-Rad Gene Pulser), where the cells receive an electric shock (2.5 kV, 200 ⁇ , 25 ⁇ F).
• an electric shock 2.5 kV, 200 ⁇ , 25 ⁇ F
• Sequencing of positive clones Selected positive clones are subjected to extraction of plasmid DNA (QIAprep miniprep kit—Qiagen) and sequenced by the core sequencing (310 Applied Biosystems) of the University Centre of Pavia (BMR Genomics, Cribi). Vectors containing an error-free cassette are used as templates in the subsequent phases.
• EcK4wt cells grown in LB medium for about 2 hours are washed with distilled water and resuspended in 50 ⁇ L of an aqueous solution of glycerol 10% v/v.
• electrocompetent cells were transformed with 800 ng of linear DNA fragment containing the complete cassette. The latter is obtained using L-pGaprfaH as template and pK4_up and rfah_dw primers.
• bacterial isolates are obtained that contain multiple copies of the pGapRfaH construct lacking the selection marker.
• Table 2 shows the sequence of the pgapP1-rfaH promoter cassette.
• the strategy used for construction of recombinant EcK4r2 involves the integration, into the multiple copies (1-5) of the endogenous PK4 plasmid of EcK4wt, of an expression cassette containing the rfaH gene under control of pGapP1-P4 (four promoter system P1-P2-P3-P4 of the gene encoding glyceraldehyde-3-P dehydrogenase, GAPDH) in order to obtain constant transcription of the rfaH gene throughout the growth phase.
• pGapP1-P4 four promoter system P1-P2-P3-P4 of the gene encoding glyceraldehyde-3-P dehydrogenase, GAPDH
• Example 1 The procedure is carried out as described in Example 1, except that, in this case, the construction of the cassette to be integrated in PK4 involves amplification of the whole pGapP1-P4 promoter from the EcK4wt genome.
• the integration site identified in PK4 is the same as in example 1. Therefore the operations for adaptation of the integration cassette are as described in Example 1, making use of the primers shown in Table 3 for amplification experiments.
• EcK4r3 E. coli K4 recombinant 3
• Amplification of the functional cassette (fragment I)—The cassette provided in the kit is amplified using the primer pair Lacz_up and FRT_dw (Table 1).
• the LacZ_up oligo contains the 100 bp region similar to the 5′ portion of the LacZ gene where the recombination event is meant to be directed.
• the PCR profile used was: 94° C. for 2′; 25 cycles: 94° C. for 1′, 56° C. for 1′, 72° C. for 2′; 72° C. for 7′.
• Amplification of the rfaH gene is carried out using EcK4wt chromosomal DNA as template and primers rfaH_up and LacZ_dw.
• the latter contains 100 bp which are homologous to the 3′ portion of the segment located downstream of the LacZ gene in the EcK4wt genome, where the recombination event is meant to be directed.
• the PCR profile used was: 94° C. for 2′; 25 cycles: 94° C. for 1′, 56° C. for 1′, 72° C. for 30′′; 72° C. for 7′.
• Primer Sequence P1 LacZ_up 5′ CAC CCT GGC GCC CAA TAC GCA AAC CGC CTC TCC CCG CGC GTT GGC CGA TTC ATT AAT GCA GCT GGC ACG ACA GGT TTC CCG ACT GGA AAG CGG GCA GTG AAA TTA ACC CTC ACT AAA GGG CGG 3′ (SEQ ID NO: 11)
• Example 1 The procedure is as in Example 1 with the only difference that the complete cassette contained in the linear DNA fragment is obtained using XL-pGaprfaH as template and primers LacZ_Up e LacZ_Dw.
• Table 5 shows the sequence of the pgapP1-rfaH promoter cassette.
• the strategy used for construction of the recombinant EcK4r4 involves engineering EcK4wt by use of insertional mutagenesis based on the use of transposable elements. To this end, the characteristics of the E. coli gene cluster have been exploited, namely the presence of the IS2 insertion sequence and the experimental evidence that rfaH overexpression can influence production of the K4 polysaccharide.
• the IS2 sequence contains a promoter followed by a gene encoding a transposase, these genes have flanking sequences termed IRL (LIR) and RIR.
• IRL flanking sequences
• RIR flanking sequences
• the strategy is based on construction of a modified IS2 element containing the rfaH gene in place of the transposase encoding gene.
• IRL, RIR and rfaH were amplified from E. coli K4 genomic DNA, using primers reported in Table 6, and subsequently digested with appropriate restriction enzymes to create fragments with compatible ends and ready to be subjected to a ligation reaction.
• the resulting fragment (IRL-rfaH-RIR) was amplified and inserted into the XL cloning vector (Invitrogen) that was subsequently used to transform E. coli K4 cells.
• a random integration event/events took place independently (after the evolution cycles for expulsion of the vector and establishment of a stable mutant, e.g. 3 consecutive growth cycles in flask during 24 h) yielding a mutant with at least one copy of the rfaH gene overproducing the K4 polysaccharide.
• the mutant strains EcK4r1, EcK4r2 and EcK4r3 and the wild type strain EcK4wt are grown in flask, varying the nutrient sources: medium 1, glycerol 10 g ⁇ L ⁇ 1 +soy 1 g ⁇ L ⁇ 1 ; medium 2, glycerol 10 g ⁇ L ⁇ 1 +casamino acids 2 g ⁇ L ⁇ 1 ; medium 3, glucose 10 g ⁇ L ⁇ 1 +yeast extract 1 g ⁇ L ⁇ 1 ; medium 4, glucose 10 g ⁇ L ⁇ 1 +yeast extract 2 g ⁇ L ⁇ 1 .
• All media have a pH of 7.5 and contain the same salt solution: K2HPO 4 10 g ⁇ L ⁇ 1 ; KH 2 PO 4 2 g ⁇ L ⁇ 1 ; MgCl 2 0.1 g ⁇ L ⁇ 1 ; sodium citrate 0.5 g ⁇ L ⁇ 1 (NH 4 ) 2 SO 4 1 g ⁇ L ⁇ 1 .
• recombinant strains have an average production of K4 capsular polysaccharide which is 1.8 to 3.0 fold higher than the wild type strain (Table 8).
• the genetic stability of recombinants is evaluated by successive growth cycles carried out in flask, which confirm that the observed productivity levels are maintained. PCR analyses performed after each growth cycle show that the constructs are still present in the genetic material of recombinants after 10 days of culture.
• EcK4r1, EcK4r2 and EcK4r3 mutant strains and of the wild type EcK4wt strain is carried out in a 2.5 L bioreactor (Biostat C Plus of B. Biotech International, Melsungen, Germany) equipped with a digital control unit (DCU) for continuous measurement of the fermentation parameters (pH, pO 2 , agitation speed, aeration, temperature). Growth is carried out using culture media 1 and 4 reported in Table 8 of Example 5. Registration and control of fermentation parameters are managed through the Multi Fermentor Control System data acquisition program for Windows NT (MFCS/win software B. Braun Biotech International). A variable volume of the culture from flask is used as inoculum, that is calculated to give a starting OD 600 between 0.08 and 0.10.
• the fermentation conditions used were: temperature 37° C.; pH 7.5 controlled by NH 4 OH (50% v/v) or H 2 SO 4 (30% v/v) addition; initial concentration of glycerol 10 g ⁇ L ⁇ 1 ; initial agitation value 500 rpm; initial air flow value 2-3 Lmin ⁇ 1 (agitation and aeration are automatically adjusted during fermentation to ensure that the pO 2 is higher than 20% at any time. Growth course is monitored by measuring the absorbance at 600 nm, the kinetics of glycerol consumption, the formation of organic acids and the production of K4 capsular polysaccharide. Growth is generally interrupted at the beginning of the stationary phase of growth after 20-24 h from the start of fermentation. As reported in Table 9, the productivity recombinant strains in the best medium is 1.3 to 1.8 fold higher than the wild type strain.
• the procedure is as described for batch fermentations in Example 5, using the same culture media, except that after 5-7 hours, when pO 2 and pH values increase, the fed phase is started and carried out for an average of 25 hours.
• the addition of nutrients is maintained below the rate of substrate uptake to avoid the phenomenon of overflow metabolism. This is achieved in a metabolically controlled manner by adjusting the addition of nutrients according to the pO 2 of the medium, which must be maintained at about 30%.
• the DOT Dissolved Oxygen Tension
• controlled addition of a concentrated solution of nutrients is realized by means of a PID controller connected to a feeding pump supplying the nutrients.
• the concentrated nutrient solutions used are: medium 1 glycerol 4000 g ⁇ L ⁇ 1 +soy flour 40 g ⁇ L ⁇ 1 w/v; medium 2 glucose 400 g ⁇ L ⁇ 1 +yeast extract 80 g ⁇ L ⁇ 1 .
• the recombinant strains use: For medium 1, about 60 g ⁇ L ⁇ 1 of glycerol and 5.8 g ⁇ L ⁇ 1 of soy with a production of K4 capsular polysaccharide which is 1.4-1.8 fold higher than that of wild type (Table 10) but consumes 38% more nutrients; for medium 4, 68 g ⁇ L ⁇ 1 of glucose and 13.6 g ⁇ L ⁇ 1 YE, with a production of K4 capsular polysaccharide which is 1.5-1.9 fold higher than that of wild type (Table 9) but consumes 40% more nutrients.
• microfiltration modules are activated for replacement of the depleted medium.
• the microfiltration phase lasts an average of 35 h.
• the microfiltration process is carried out using a hollow fiber module made of polyethersulfone with cut-off of 0.22 ⁇ m, and an area comprised between 0.02 and 0.1 m 2 .
• Examples of operating ranges of MF process parameters are: Capacity for tangential flow recirculation 6-10 Lmin ⁇ 1 ; trans-membrane pressure 0.8-1.2 atm; room temperature. The exchange of 1 volume of culture in approximately 2-4 h was obtained under these conditions.
• the rate of nutrient addition is controlled so as to maintain the pO 2 of the culture medium at about 30%, using a PID controller connected to the feeding pump supplying the nutrients.
• a PID controller connected to the feeding pump supplying the nutrients.
• feeding is automatically activated until reaching the pO 2 set point.
• the feeding pump stabilizes at a minimum value of rounds/minute in order to ensure, unlike fed-batch experiments, the maintenance of a minimum concentration of carbon in the fermentation vessel, despite the continuous supply of medium.
• the depletion of the carbon source determines again a sudden rise of the pO 2 value, triggering a new feeding round at a rotation speed of the peristaltic pump which is higher than the minimum that was set by default.
• the volume of bacterial culture is kept constant by a special control loop (level controller) by addition of a mineral salt solution which is identical to that used in the growth medium.
• a mineral salt solution which is identical to that used in the growth medium.
• backflushing is performed every hour to decrease the fouling effects during microfiltration.
• agitation and ventilation were varied from 250 to 1.000 rpm and from 1 to 1.6 Lmin ⁇ 1 , respectively, to maintain the percentage of dissolved oxygen close to 20% saturation.
• recombinant strains use: for medium 1, about 130 gL ⁇ 1 of glycerol and 13 gL ⁇ 1 of soy with a production of K4 capsular polysaccharide which is 2.2-2.6 fold higher than that of wild type (Table 10) but consumes 30% more nutrients; for medium 4, about 90-100 g ⁇ L ⁇ 1 of glucose and 18-20 g ⁇ L ⁇ 1 YE, with a production of K4 capsular polysaccharide which is 2.3-2.7 fold higher than that of wild type (Table 11) but consumes 25% more nutrients.
• the volume of microfiltrate is about 10-12 L and the amount of K4 capsular polysaccharide found in the microfiltrate is 25-30% of the total product.
• the recombinant strain EcK4r3 is employed using culture medium 1 from Example 4.
• the fermentation product (40-60 L) obtained from a batch process as described in Example 5, and using a 75 L fermentor, is used as inoculum.
• the inoculum is incubated in the fermentor for 6-8 h until a cell density of 5 ⁇ 1 OD 600 is reached.
• the m 3 production scale employs a 1.2 m 3 fermentor containing 1 m 3 of culture medium. Fermentation is carried out by the same strategy described in Example 7, except that an external microfiltration unit is used that consists of a hollow fiber module with a 8-10 m 2 filter area operating at a tangential flow of 10 Lmin ⁇ 1 .
• the duration of batch and fed-batch phases is 5-7 h and 4-6 h, respectively.
• 40 L of concentrated solution of nutrients are added overall, for a total of 12.5 kg of glucose and 2.5 kg of yeast extract.
• the phase in microfiltration regimen lasts 24-36 h and the volume of the microfiltrate is 6-7 m 3 .
• the example describes the downstream processing of a fermentation broth obtained as described in Example 9.
• the cellular component is removed from the culture broth (1000 L) by continuous centrifugation using an alpha-laval centrifuge (Clara80) operating at 6000 rpm at 15-25° C.
• the microfiltrate from the last phase of fermentation (7000 L) is added to the clear supernatant, followed by addition of a protease (flavourzyme) from Aspergillus oryzae (10 ⁇ LL ⁇ 1 , 500 Ug ⁇ 1 , 2-5 UL ⁇ 1 final) and incubation with stirring for 2 h at room temperature or at 4° C. for 12-16 h to hydrolyze proteins.
• the solution is subsequently ultrafiltered on a micro/ultra/diafiltration tangential Millipore system mounted on a special skid with a reservoir capacity of 1 m 3 , equipped with hollow fiber modules or cassettes (100 kDa cutoff, filter area 40 m 2 ).
• diafiltration is carried out with ultrapure water (HPW) at a constant volume, until a residual conductivity below 500 ⁇ Si ⁇ cm (5 volumes) is obtained.
• HPW ultrapure water
• 1% v/v acetic acid is then added and the solution is heated at 100° C. for 1.25 h.
• the solution is initially concentrated (2-5 ⁇ ) and then diafiltrated until conductivity is less than 80-100 ⁇ Sicm ⁇ 1 .
• the solution is then esiccated by lyophilisation.
• the overall yield of the purification process is 75%. 4,790 g of chondroitin sodium salt are obtained with the following specifications: white powder, 12% residual H 2 O content, purity >95%, MW 38 ⁇ 2 kDa.
• the example describes the downstream processing of a fermentation broth obtained as described in Example 8.
• the cellular component is removed from the culture broth (1,000 L) by continuous centrifugation using an alpha-laval centrifuge (Clara80) operating at 6000 rpm at 15-25° C.
• the microfiltrate from the last phase of fermentation (7000 L) is added to the clear supernatant, followed by addition of 4% v/v acetic acid until a pH between 2.8 and 3.0, heating the solution at 100° C. for 1 h.
• These conditions result in defructosylation of the K4 capsular polysaccharide and splitting of lipid A from LPS which precipitates as a waxy solid. The latter is separated by sedimentation at 4° C.
• the clear solution (approximately 7.500 L), adjusted to pH 7 by addition of NaOH and supplemented with NaCl to 0.1 M concentration, is subjected to ultrafiltration-diafiltration using the above described apparatus equipped with cassettes/hollow fiber modules (10 m 2 ) made of polyethersulfone with a cutoff of 50 KDa.
• the solution is concentrated (40 ⁇ ) and diafiltrated until conductivity is below 80-100 ⁇ Sicm ⁇ 1 .
• the solution about 200 L, is supplemented with NaCl to 0.1 M final concentration and then with 2 volumes of 95% ethanol for precipitation of sodium chondroitin.
• the example describes the downstream processing of a fermentation broth obtained as described in Example 8, using only membrane processes.
• the cellular component is removed from the culture broth present in the fermentor (1.000 L) extending the microfiltration phase without the addition of saline.
• concentration by microfiltration is again performed to 300 L to increase recovery of the capsular polysaccharide; this washing step is repeated 2 times.
• the fermentation broth devoid of cells (approximately 1200 L) is treated as described in Example 9, first with protease, then by hydrolysis with acetic acid and finally ultrafiltrated-diafiltrated.
• the so obtained concentrate is esiccated by a spray-drier
• the overall yield of the purification process is 90%.
• 5,750 g of chondroitin sodium salt are obtained with the following specifications: white powder, 10% residual H 2 O content, purity >93%, MW 38 ⁇ 2 kDa.
• the example describes the downstream processing of a fermentation broth obtained as described in Example 8.
• the culture broth (1.000 L) is supplemented with trichloroacetic acid (TCA 50% v/v) to 5% of the volume, until pH ⁇ 4.
• TCA trichloroacetic acid
• This broth is then filtered on diatomaceous earth or celite with the aid of a FUNDA type plate filter.
• the clarified broth is microfiltered with the aid of an asymmetric capsular device (0.2-0.6 m; GE) in dead-end mode and neutralized by addition of NaOH.
• microfiltrate About 7.000 L of microfiltrate are added to this material, and the clarified broth is subsequently concentrated by ultrafiltration and diafiltration; when the volume is reduced to 200 L, diafiltration with ultrapure water (HPW) at constant volume is performed until residual conductivity below 500 ⁇ Sicm ⁇ 1 (5 volumes) is obtained. 1% v/v acetic acid is then added and the solution is heated at 100° C. for 1.25 h.
• HPW ultrapure water
• the clear supernatant (160 L), adjusted to pH 7 by addition of NaOH and supplemented with NaCl until 0.2M concentration, is subjected to ultrafiltration-diafiltration using the same Millipore apparatus equipped with cassettes/hollow fiber modules (10 m 2 ) made of polyethersulfone or polypropylene with a cutoff of 50 KDa.
• the solution is initially concentrated (3 ⁇ ) and then diafiltrated until the conductivity is below 100 ⁇ Sicm ⁇ 1 .
• the solution brought to 0.125M NaCl is supplemented with 2 volumes of acetone to precipitate the chondroitin.
• the precipitate, collected on filters or sedimented, is dried in an oven at 40° C.
• the overall yield of the purification process is 70%. 4,480 g of chondroitin are obtained with the following specifications: white powder, 12% residual H 2 O content, purity >92%, MW 35 ⁇ 2 kDa.

Landscapes

• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Health & Medical Sciences (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Steroid Compounds (AREA)

Applications Claiming Priority (4)

Publications (2)

Family

ID=41665067

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (13)

Citations (6)

Family Cites Families (1)

• 2009
  • 2009-05-25 IT ITMI2009A000923A patent/IT1394311B1/it active
• 2010
  • 2010-05-25 US US13/322,185 patent/US8592186B2/en active Active
  • 2010-05-25 WO PCT/EP2010/057129 patent/WO2010136435A1/fr active Application Filing
  • 2010-05-25 HU HUE10730105A patent/HUE038895T2/hu unknown
  • 2010-05-25 PL PL10730105T patent/PL2435578T3/pl unknown
  • 2010-05-25 PT PT107301053T patent/PT2435578T/pt unknown
  • 2010-05-25 SI SI201031706T patent/SI2435578T1/en unknown
  • 2010-05-25 CA CA2763955A patent/CA2763955C/fr active Active
  • 2010-05-25 CN CN201080032889.1A patent/CN102459625B/zh active Active
  • 2010-05-25 DK DK10730105.3T patent/DK2435578T3/en active
  • 2010-05-25 ES ES10730105.3T patent/ES2676755T3/es active Active
  • 2010-05-25 EP EP10730105.3A patent/EP2435578B1/fr active Active

Patent Citations (6)

Non-Patent Citations (13)

Also Published As

Similar Documents

Legal Events